[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maximilian Pfau\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100632579","enhanced-vision-and-imaging-tests-for-enabling-treatment-trials-in-early-and-intermediate-amd-100632579",false,"NCT07515521","Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD","EVITE-AMD","Inclusion Criteria:\n\n* Written informed consent.\n* All biological sexes and gender identities.\n* Age \\>=18 years for healthy volunteers; age \\>=55 years for participants with AMD.\n* Ability to understand German or English sufficiently for study information and procedures.\n\nAdditional Inclusion Criteria by Cohort:\n\nHealthy Volunteers:\n\n\\- No drusen \\>63 um and no subretinal drusenoid deposits in either eye.\n\nEarly AMD:\n\n\\- Study eye with drusen \\>63 um but \\\u003C125 um and no pigmentary changes.\n\nIntermediate AMD:\n\n\\- Study eye with drusen \\>125 um and\u002For pigmentary changes.\n\nExclusion Criteria:\n\n* Claustrophobia relevant to dark-adaptation procedures.\n* Hypersensitivity to indocyanine green or sodium iodide, iodine allergy, or hyperthyroidism.\n* Known pregnancy.\n* Study eye history of ocular surgery other than cataract surgery, YAG capsulotomy, or laser retinopexy.\n* Ocular disease in the study eye that could affect visual function testing in the opinion of the investigators.\n* Medical conditions or planned operations that could interfere with follow-up.\n* Inability to comply with study procedures or insufficient language skills in the study language.\n* Inability to provide informed consent.",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This monocentric prospective longitudinal observational study will validate fundus-tracked dark adaptometry as an endpoint for future treatment trials in early and intermediate age-related macular degeneration (AMD). The study will characterize normative cone- and rod-mediated dark adaptation parameters in healthy volunteers, assess test-retest reliability, quantify sensitivity to change over time, evaluate diagnostic and prognostic validity against AMD stage and structural progression, and investigate imaging-, biomarker-, and genetics-based determinants of impaired dark adaptation.",[25],"Age - Related Macular Degeneration (AMD)",[27],"AMD","RECRUITING","2026-03-31",{"date":31,"type":32},"2026-04-07","ACTUAL",{"date":34,"type":32},"2026-02-15",{"date":36,"type":21},"2028-12-15",{"name":38,"class":39},"Maximilian Pfau","OTHER",""]